文献速递支持与姑息治疗

免疫检查点抑制剂多器官免疫相关不良事件的回顾性多队列研究及其后续意义

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
PubMed 文献 · Lancet Oncol · 2024-07-15

本研究基于美国麻省总医院、布莱根妇女医院与丹娜-法伯癌症研究所队列(MGBD)及TriNetX数据库,回顾性识别接受免疫检查点抑制剂的患者,采用倾向评分匹配、成对相关分析、非负矩阵分解与层次聚类识别多器官免疫相关不良事件的共现模式,并分析其与总生存的关系。共现事件可分解为内分泌、皮肤、呼吸、消化、肝脏、肌肉骨骼和神经七个器官相关因素与患者聚类,不同聚类预后不同,结果在TriNetX队列中得到验证。

要点

  • MGBD队列中内分泌(HR 0·53,95%CI 0·40-0·70,p<0·0001)与皮肤(HR 0·61,95%CI 0·46-0·81,p=0·0007)聚类总生存较好。
  • MGBD队列中呼吸聚类总生存不利(HR 1·60,95%CI 1·25-2·03,p=0·0001),其余聚类为不利或中性。
  • TriNetX队列结果相似,但神经聚类为不利(HR 1·30,95%CI 1·06-1·59,p=0·013)而非中性。

核心结论

  • 可靠识别患者所属的免疫相关不良事件聚类可为免疫治疗预后判断提供有价值的临床信息,并可用于告知患者其个体化免疫相关不良事件组合的临床影响,最终制定更个性化的监测与缓解策略。

研究设计与样本

  • 回顾性研究,从MGBD队列(2015年5月31日至2022年6月29日)与TriNetX网络(2010年4月30日至2021年10月11日)识别接受七种常见免疫检查点抑制剂的患者。
  • MGBD队列与TriNetX队列按人口学、肿瘤及免疫检查点抑制剂特征进行1:2倾向评分匹配。
  • 采用成对相关分析、非负矩阵分解与层次聚类识别共现模式,并以6个月界标时间点进行总生存分析。
  • MGBD识别15 246例免疫检查点抑制剂接受者,TriNetX识别50 503例,倾向评分匹配队列分别纳入13 086例与26 172例。
  • MGBD中位随访317天(IQR 113-712),TriNetX中位随访249天(91-616)。

主要发现

  • 应用免疫相关不良事件识别规则后,MGBD保留8704例,其中3284例(37·7%)有、5420例(62·3%)无免疫相关不良事件;TriNetX保留18 162例,其中5538例(30·5%)有、12 624例(69·5%)无免疫相关不良事件。
  • 两队列中均常见免疫相关不良事件的正向成对相关。
  • 共现事件被分解为七个跨器官因素,对应七个患者聚类:内分泌、皮肤、呼吸、消化、肝脏、肌肉骨骼和神经。
  • MGBD队列6个月界标时间点:内分泌聚类HR 0·53(95%CI 0·40-0·70,p<0·0001)、皮肤聚类HR 0·61(95%CI 0·46-0·81,p=0·0007)总生存有利;呼吸聚类HR 1·60(95%CI 1·25-2·03,p=0·0001)不利;消化聚类HR 0·86(95%CI 0·67-1·10,p=0·23)、肌肉骨骼聚类HR 0·97(95%CI 0·78-1·21,p=0·78)、肝脏聚类HR 1·20(95%CI 0·91-1·59,p=0·19)、神经聚类HR 1·30(95%CI 0·97-1·74,p=0·074)为中性。
  • TriNetX队列结果相似:内分泌聚类HR 0·75(95%CI 0·60-0·93,p=0·0078)、皮肤聚类HR 0·62(95%CI 0·48-0·82,p=0·0007)、呼吸聚类HR 1·21(95%CI 1·00-1·46,p=0·044),神经聚类为不利(HR 1·30,95%CI 1·06-1·59,p=0·013)而非中性。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出推荐;作者认为可靠识别患者所属的免疫相关不良事件聚类可为免疫治疗预后判断提供有价值的临床信息,并可用于告知患者其个体化免疫相关不良事件组合的临床影响、最终制定更个性化的监测与缓解策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding co-occurrence patterns and prognostic implications of immune-related adverse events is crucial for immunotherapy management. However, previous studies have been limited by sample size and generalisability. In this study, we leveraged a multi-institutional cohort and a population-level database to investigate co-occurrence patterns of and survival outcomes after multi-organ immune-related adverse events among recipients of immune checkpoint inhibitors. METHODS: In this retrospective study, we identified individuals who received immune checkpoint inhibitors between May 31, 2015, and June 29, 2022, from the Massachusetts General Hospital, Brigham and Women's Hospital, and Dana-Farber Cancer Institute (Boston, MA, USA; MGBD cohort), and between April 30, 2010, and Oct 11, 2021, from the independent US population-based TriNetX network. We identified recipients from all datasets using medication codes and names of seven common immune checkpoint inhibitors, and patients were excluded from our analysis if they had incomplete information (eg, diagnosis and medication records) or if they initiated immune checkpoint inhibitor therapy after Oct 11, 2021. Eligible patients from the MGBD cohort were then propensity score matched with recipients of immune checkpoint inhibitors from the TriNetX database (1:2) based on demographic, cancer, and immune checkpoint inhibitor characteristics to facilitate cohort comparability. We applied immune-related adverse event identification rules to identify patients who did and did not have immune-related adverse events in the matched cohorts. To reduce the likelihood of false positives, patients diagnosed with suspected immune-related adverse events within 3 months after chemotherapy were excluded. We performed pairwise correlation analyses, non-negative matrix factorisation, and hierarchical clustering to identify co-occurrence patterns in the MGBD cohort. We conducted landmark overall survival analyses for patient clusters based on predominant immune-related adverse event factors and calculated accompanying hazard ratios (HRs) and 95% CIs, focusing on the 6-month landmark time for primary analyses. We validated our findings using the TriNetX cohort. FINDINGS: We identified 15 246 recipients of immune checkpoint inhibitors from MGBD and 50 503 from TriNetX, of whom 13 086 from MGBD and 26 172 from TriNetX were included in our propensity score-matched cohort. Median follow-up durations were 317 days (IQR 113-712) in patients from MGBD and 249 days (91-616) in patients from TriNetX. After applying immune-related adverse event identification rules, 8704 recipients of immune checkpoint inhibitors were retained from MGBD, of whom 3284 (37·7%) had and 5420 (62·3%) did not have immune-related adverse events, and 18 162 recipients were retained from TriNetX, of whom 5538 (30·5%) had and 12 624 (69·5%) did not have immune-related adverse events. In both cohorts, positive pairwise correlations of immune-related adverse events were commonly observed. Co-occurring immune-related adverse events were decomposed into seven factors across organs, revealing seven distinct patient clusters (endocrine, cutaneous, respiratory, gastrointestinal, hepatic, musculoskeletal, and neurological). In the MGBD cohort, the patient clusters that predominantly had endocrine (HR 0·53 [95% CI 0·40-0·70], p<0·0001) and cutaneous (0·61 [0·46-0·81], p=0·0007) immune-related adverse events had favourable overall survival outcomes at the 6-month landmark timepoint, while the other clusters either had unfavourable (respiratory: 1·60 [1·25-2·03], p=0·0001) or neutral survival outcomes (gastrointestinal: 0·86 [0·67-1·10], p=0·23; musculoskeletal: 0·97 [0·78-1·21], p=0·78; hepatic: 1·20 [0·91-1·59], p=0·19; and neurological: 1·30 [0·97-1·74], p=0·074). Similar results were found in the TriNetX cohort (endocrine: HR 0·75 [95% CI 0·60-0·93], p=0·0078; cutaneous: 0·62 [0·48-0·82], p=0·0007; respiratory: 1·21 [1·00-1·46], p=0·044), except for the neurological cluster having unfavourable (rather than neutral) survival outcomes (1·30 [1·06-1·59], p=0·013). INTERPRETATION: Reliably identifying the immune-related adverse event cluster to which a patient belongs can provide valuable clinical information for prognosticating outcomes of immunotherapy. These insights can be leveraged to counsel patients on the clinical impact of their individual constellation of immune-related adverse events and ultimately develop more personalised surveillance and mitigation strategies. FUNDING: US National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wan G, Chen W, Khattab S, et al. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol. 2024. PMID: 39025103. doi:10.1016/S1470-2045(24)00278-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。